RELAFEN DS
Generic: NABUMETONE
Carwin Pharmaceutical AssociatesManufacturer
ORALRoute
NABUMETONEActive Substance
2019-08-30Original Approval
RELAFEN DS is FDA application ANDA203166, sponsored by LGM PHARMA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
DRUG INEFFECTIVE
514 reports
2
PAIN
470 reports
3
NAUSEA
376 reports
4
FATIGUE
362 reports
5
HEADACHE
320 reports
6
ARTHRALGIA
314 reports
7
DYSPNOEA
245 reports
8
DIARRHOEA
241 reports
9
PAIN IN EXTREMITY
227 reports
10
DIZZINESS
224 reports